Synairgen starts dosing inhaled COVID-19 drug in phase 3 trialUK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after Share XSynairgen starts dosing inhaled COVID-19 drug in phase 3 trialhttps://pharmaphorum.com/news/synairgen-starts-dosing-inhaled-covid-19-drug-in-phase-3-trial/
Merck & Co plans to file cough drug gefapixant after phase 3 successMerck & Co is planning to file a drug for unexplained or treatment-resistant cough after supportive results from Share XMerck & Co plans to file cough drug gefapixant after phase 3 successhttps://pharmaphorum.com/news/merck-co-plans-to-file-cough-drug-gefapixant-after-phase-3-success/
PureTech to develop drug to treat lung scarring in COVID-19 patientsUS biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and Share XPureTech to develop drug to treat lung scarring in COVID-19 patientshttps://pharmaphorum.com/news/puretech-to-develop-drug-to-treat-lung-scarring-in-covid-19-patients/
FREE TO ATTEND | Inhalation & Respiratory Drug Delivery Event: Virtual08 – 09 July 2020 | BST (UTC+1) | FREE TO ATTEND Share XFREE TO ATTEND | Inhalation & Respiratory Drug Delivery Event: Virtualhttps://pharmaphorum.com/partner-content/free-to-attend-inhalation-respiratory-drug-delivery-event-virtual/
FREE TO ATTEND | Formulation & Drug Delivery Event: VirtualFREE TO ATTEND Share XFREE TO ATTEND | Formulation & Drug Delivery Event: Virtualhttps://pharmaphorum.com/partner-content/free-to-attend-formulation-drug-delivery-event-virtual/
Verona says FDA backs plan to take COPD drug into phase 3More than two years after first saying it would take its lead drug into a pivotal trial, Verona Share XVerona says FDA backs plan to take COPD drug into phase 3https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/
Novartis on point in EU for asthma triple as CHMP backs EnerzairNovartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now Share XNovartis on point in EU for asthma triple as CHMP backs Enerzairhttps://pharmaphorum.com/news/novartis-on-point-in-eu-for-asthma-triple-as-chmp-backs-enerzair/
Chiesi starts rare diseases division, ahead of potential Fabry disease filingItalian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch Share XChiesi starts rare diseases division, ahead of potential Fabry disease filinghttps://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/
FDA clears emergency diagnostic as coronavirus fears mountThe US drugs regulator has approved emergency use of a diagnostic for the strain of coronavirus causing the Share XFDA clears emergency diagnostic as coronavirus fears mounthttps://pharmaphorum.com/news/fda-clears-emergency-diagnostic-as-coronavirus-fears-mount/